Overview
BCTX market data
Price History
BCTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$62.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.56 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.68 – $20.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $41.2M · P/B 0.70.
Company News
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate CancerBenzinga · Aug 5, 2026, 11:33 AM
Odette Cancer Centre At Sunnybrook Health Sciences Centre Joined BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast CancerBenzinga · Jul 16, 2026, 11:36 AM
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMTBenzinga · Jul 15, 2026, 11:35 AM
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMTBenzinga · Jul 7, 2026, 11:40 AM
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMTBenzinga · Jun 25, 2026, 11:45 AM
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoYBenzinga · Jun 9, 2026, 10:08 PM
BriaCell Therapeutics Presents Positive Clinical Data For Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor And Further Analysis Of Phase 2 Data At ASCO Annual Meeting May 29 - June 2Benzinga · Jun 1, 2026, 11:43 AM
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and ResearchBenzinga · Jun 1, 2026, 7:51 AM
BriaCell Therapeutics Receives Sixth Positive Recommendation From Independent Data Safety Monitoring Board For Its Pivotal Phase 3 Bria-ABC Trial Of Bria-IMT Plus Immune Checkpoint InhibitorBenzinga · May 26, 2026, 11:33 AM
BriaCell Therapeutics Presents Positive Clinical Data From Three Clinical Data Poster Presentations, Three Publication-Only Abstracts At 2026 ASCO Annual MeetingBenzinga · May 22, 2026, 11:35 AM